Together, these approaches will help clarify whether CAP’s effects on MASLD stem from direct hepatic TRPV1 activation or result primarily from its systemic anti-obesity properties. The gene discussed is TRPV1; the disease is obesity due to melanocortin 4 receptor deficiency.